AU2008353479B2 - Anti-VEGF antibody - Google Patents

Anti-VEGF antibody Download PDF

Info

Publication number
AU2008353479B2
AU2008353479B2 AU2008353479A AU2008353479A AU2008353479B2 AU 2008353479 B2 AU2008353479 B2 AU 2008353479B2 AU 2008353479 A AU2008353479 A AU 2008353479A AU 2008353479 A AU2008353479 A AU 2008353479A AU 2008353479 B2 AU2008353479 B2 AU 2008353479B2
Authority
AU
Australia
Prior art keywords
antibody
amino acid
seq
acid residues
variable domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2008353479A
Other languages
English (en)
Other versions
AU2008353479A1 (en
Inventor
Yaohuang Ke
Guo-Liang Yu
Weimin Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epitomics Inc
Original Assignee
Epitomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epitomics Inc filed Critical Epitomics Inc
Publication of AU2008353479A1 publication Critical patent/AU2008353479A1/en
Application granted granted Critical
Publication of AU2008353479B2 publication Critical patent/AU2008353479B2/en
Priority to AU2014202474A priority Critical patent/AU2014202474B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2008353479A 2008-03-26 2008-10-08 Anti-VEGF antibody Active AU2008353479B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2014202474A AU2014202474B2 (en) 2008-03-26 2014-05-07 Anti-VEGF antibody

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3971908P 2008-03-26 2008-03-26
US61/039,719 2008-03-26
PCT/US2008/011620 WO2009120178A1 (en) 2008-03-26 2008-10-08 Anti-vegf antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2014202474A Division AU2014202474B2 (en) 2008-03-26 2014-05-07 Anti-VEGF antibody

Publications (2)

Publication Number Publication Date
AU2008353479A1 AU2008353479A1 (en) 2009-10-01
AU2008353479B2 true AU2008353479B2 (en) 2014-02-20

Family

ID=41114205

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008353479A Active AU2008353479B2 (en) 2008-03-26 2008-10-08 Anti-VEGF antibody

Country Status (9)

Country Link
US (2) US7803371B2 (enExample)
EP (1) EP2259795B1 (enExample)
JP (2) JP5823858B2 (enExample)
KR (1) KR101581244B1 (enExample)
CN (2) CN102065888B (enExample)
AU (1) AU2008353479B2 (enExample)
BR (1) BRPI0822556B1 (enExample)
CA (3) CA2719400C (enExample)
WO (1) WO2009120178A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2307454T (pt) 2008-06-25 2017-04-26 Esbatech Alcon Biomed Res Unit Anticorpos estáveis e solúveis que inibem o vegf
CN102002104A (zh) * 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物
WO2011047442A1 (en) * 2009-10-23 2011-04-28 Garvan Institute Of Medical Research Modified variable domain molecules and methods for producing and using same
BR112013021863A2 (pt) 2011-03-03 2016-11-22 Apexigen Inc anticorpos anti-receptor il-6 e métodos de uso
CN104650229A (zh) * 2011-11-02 2015-05-27 埃派斯进有限公司 抗-kdr抗体和使用方法
CN103417964A (zh) * 2012-05-17 2013-12-04 江苏先声药物研究有限公司 一种抗vegf抗体的用途
CN103417965B (zh) * 2012-05-17 2018-04-13 江苏先声药业有限公司 一种含有抗vegf抗体的药物组合物
US9745558B2 (en) 2013-02-18 2017-08-29 Vegenics Pty Limited VEGFR-3 ligand binding molecules and uses thereof
JP2016530244A (ja) * 2013-12-31 2016-09-29 ディベロップメント センター フォー バイオテクノロジーＤｅｖｅｌｏｐｍｅｎｔ Ｃｅｎｔｅｒ Ｆｏｒ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ 抗ｖｅｇｆ抗体及びその使用
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
US20180142038A1 (en) * 2015-01-16 2018-05-24 ALDER BIOPHARMACEUTICALS, INC. a/b/a ALDERBIO HOLDINGS LLC Anti-glycoprotein antibodies and uses thereof
CN107849105B (zh) * 2015-07-06 2021-09-17 Ucb生物制药有限责任公司 Tau结合抗体
GB201601073D0 (en) * 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
KR20220093103A (ko) * 2019-09-13 2022-07-05 어드메어 테라퓨틱스 소사이어티 항종양용해 바이러스 항원 항체 및 이의 사용 방법
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
IL321781A (en) * 2022-12-29 2025-08-01 Ltz Therapeutics Inc Anti-cd79b antibodies and uses thereof
CN118344476B (zh) * 2024-05-16 2024-11-15 武汉爱博泰克生物科技有限公司 人c反应蛋白单克隆抗体、抗体对和检测试剂或试剂盒及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000064946A2 (en) * 1999-04-28 2000-11-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1299833A (zh) * 1999-12-30 2001-06-20 华西医科大学口腔医学研究所 抗人血管内皮生长因子单链抗体及其制备方法
US20040185040A1 (en) * 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
JP2005535341A (ja) * 2002-08-15 2005-11-24 エピトミスク インコーポレーティッド ヒト化ウサギ抗体
CA2533830A1 (en) * 2003-08-07 2005-02-24 Epitomics, Inc. Methods for humanizing rabbit monoclonal antibodies
US7462697B2 (en) * 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
US7431927B2 (en) * 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
KR101834797B1 (ko) * 2008-06-25 2018-03-07 에스바테크 - 어 노바티스 컴파니 엘엘씨 보편적 항체 프레임워크를 사용한 래빗 항체의 인간화
CN102002104A (zh) * 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000064946A2 (en) * 1999-04-28 2000-11-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf

Also Published As

Publication number Publication date
HK1201280A1 (en) 2015-08-28
CN102065888A (zh) 2011-05-18
CA2981887A1 (en) 2009-10-01
CN103992405B (zh) 2016-08-17
CA2719400A1 (en) 2009-10-01
US7803371B2 (en) 2010-09-28
BRPI0822556A2 (pt) 2020-08-18
JP2014205674A (ja) 2014-10-30
CA3053675A1 (en) 2009-10-01
US20090246190A1 (en) 2009-10-01
EP2259795A4 (en) 2012-06-06
JP5823858B2 (ja) 2015-11-25
EP2259795A1 (en) 2010-12-15
WO2009120178A1 (en) 2009-10-01
BRPI0822556B1 (pt) 2022-03-03
US8088375B2 (en) 2012-01-03
US20110008367A1 (en) 2011-01-13
JP2011517447A (ja) 2011-06-09
CA2719400C (en) 2017-11-14
KR20100132983A (ko) 2010-12-20
CN102065888B (zh) 2014-03-26
KR101581244B1 (ko) 2015-12-31
AU2008353479A1 (en) 2009-10-01
CA2981887C (en) 2019-09-03
CN103992405A (zh) 2014-08-20
EP2259795B1 (en) 2016-04-06

Similar Documents

Publication Publication Date Title
AU2008353479B2 (en) Anti-VEGF antibody
US12180289B2 (en) Binding proteins and methods of use thereof
JP5738294B2 (ja) 抗ｖｅｇｆモノクローナル抗体およびその抗体を含む薬学的組成物
JP2022513694A (ja) 抗ｐｄ－ｌ１／抗４－１ｂｂ二重特異性抗体およびその使用
JP2020515251A (ja) Ｂ７−ｈ３抗体、その抗原結合フラグメント、及びそれらの医学的使用
KR20220119117A (ko) 종양 특이적 claudin 18.2 항체
WO2001031065A1 (en) Humanization of non-human, mammalian antibodies
TW202339799A (zh) 使用抗人類ｇｐｖｉ抗體抑制血小板凝集
AU2014202474B2 (en) Anti-VEGF antibody
WO2022218277A1 (zh) 一种抗fgf21羧基末端的抗体及其应用
CN115956089A (zh) 抑制性抗enpp1抗体
US20190194319A1 (en) Anti-ascl1 antibodies and methods of use
US20250092124A1 (en) Antibody molecule against growth and differentiation factor 15 and use thereof
HK1201280B (en) Anti-vegf antibody
WO2018213680A1 (en) Diagnostic antibodies and methods of use
RU2773819C2 (ru) Белок, связанный с гликопротеином человека, композиция, фармацевтическая композиция, вектор экспрессии
KR20240126876A (ko) 항-βKlotho 항체 및 이의 응용
CN117244055A (zh) Cd70抗体的药物组合物及其应用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)